Hansoh Pharma and Roche Sign $15.5 Billion ADC Strategic Collaboration and License Deal

On October 19, Hansoh Pharmaceutical announced a strategic collaboration and license agreement with Roche for ADC programs, with a total value of $15.5 billion. This is the second collaboration between the two companies in the ADC field, covering global development of novel ADC programs. The original report did not disclose specific pipelines, targets, or the breakdown of upfront and milestone payments.